TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35922819
Drug: SMC drugs
Normalized name: prosolv SMCC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMC drugs and albendazole and praziquantel
Study: 35922861
Drug: Eltanexor 10
Normalized name: Eltanexor
DrugBank: Eltanexor (DB16153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanexor 10 mg, administered on days 1-5 each week of a 28-day cycle
Study: 35922861
Drug: Eltanexor 20
Normalized name: Eltanexor
DrugBank: Eltanexor (DB16153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanexor 20 mg, administered on days 1-5 each week of a 28-day cycle
Study: 35922861
Drug: Eltanexor (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanexor (both doses combined)
Study: 35922860
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy duration
Study: 35922868
Drug: Cultivated oral
Normalized name: Cultivated mushroom
DrugBank: Cultivated mushroom (DB10544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultivated oral mucosal epithelial sheet transplantation
Study: 35923658
Drug: Aripiprazole tablets
Normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole tablets with sensor (AS) - high engagement group
Study: 35923658
Drug: Aripiprazole tablets
Normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole tablets with sensor (AS) - moderate engagement group
Study: 35923658
Drug: Aripiprazole tablets
Normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole tablets with sensor (AS) - discontinued group
Study: 35925040
Drug: Person-centred, theory-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-centred, theory-based oral health education program
Study: 35925555
Drug: Fexinidazole 1200
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexinidazole 1200 mg/day for 2 weeks
Study: 35925555
Drug: Fexinidazole 1800
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexinidazole 1800 mg/day for 2 weeks
Study: 35925686
Drug: Anticoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation treatment for acute VTE
Study: 35927231
Drug: Human umbilical
Normalized name: Human umbilical tissue derived cells
DrugBank: Human umbilical tissue derived cells (DB17907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human umbilical cord-derived mesenchymal stem cells (UMSCs) infusion
Study: 35927710
Drug: Intralesional T-VEC
Normalized name: T-Vec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intralesional T-VEC (up to 4 mL, first dose as seroconversion dose) and systemic nivolumab (240 mg flat dose) every 2 weeks for four courses of T-VEC and three doses of nivolumab
Study: 35927713
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment and use of insecticide-treated nets
Study: 35928870
Drug: UCPVax (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCPVax (therapeutic cancer vaccine composed of two peptides derived from telomerase) combined with atezolizumab (anti-PD-L1)
Study: 35929455
Drug: Insulin receptor
Normalized name: Insulin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin receptor substrate-1 rs956115 genotype
Study: 35929986
Drug: AZD5305 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5305 at doses ≥0.1 mg/kg once daily
Study: 35929986
Drug: Olaparib 100
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 100 mg/kg once daily
Study: 35930336
Drug: Weekly assessments
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly assessments during the mobile sensing phase for 9 months.
Study: 35931600
Drug: Immediate medical
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate medical treatment (IMT) started less than 3 months after metastatic diagnosis
Study: 35931600
Drug: Delayed medical
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed medical treatment (DMT)
Study: 35931600
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment of metastasis (LTM)
Study: 35931943
Drug: Tucatinib 300
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tucatinib 300 mg dose
Study: 35932306
Drug: BMC injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMC injections with higher CFU-F concentrations
Study: 35932387
Drug: Envafolimab 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envafolimab 1.0 mg/kg, 2.5 mg/kg, and 5.0 mg/kg SC QW (10 patients)
Study: 35932387
Drug: Envafolimab 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envafolimab 2.5 mg/kg and 5.0 mg/kg SC Q2W (16 patients)
Study: 35932387
Drug: Envafolimab 300
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envafolimab 300 mg SC Q4W (9 patients)
Study: 35932388
Drug: Pevonedistat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat (50 mg/m)
Study: 35932628
Drug: Nilotinib treatment
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib treatment
Study: 35932876
Drug: Asymptomatic short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asymptomatic short cervix treatment (200 mg vaginal progesterone, cerclage, or pessary)
Study: 35933358
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) treatment 2 g/kg monthly for three months
Study: 35933915
Drug: Cobicistat co-administration
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cobicistat co-administration with osimertinib
Study: 35934010
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg IV) plus tremelimumab (75 mg IV) for four cycles, followed by durvalumab alone every 4 weeks for up to 12 months.
Study: 35934287
Drug: Cilofexor 100
Normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilofexor 100 mg daily
Study: 35935379
Drug: Collection of
Normalized name: Reveos Select CPD with AS-5 Red Cell Preservative Solution For Collection Of 500ml Of Blood KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collection of PFAPA patient's demographics, medical histories, symptoms, triggers/risk factors, therapies, and impact on healthcare systems
Study: 35935445
Drug: Intramuscular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketamine (0.75 mg/kg)
Study: 35935445
Drug: Escitalopram (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (15 mg) and aripiprazole (5 mg)
Study: 35935634
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (SGLT2i) administered to Group I with inadequately controlled T2D (mean fasting plasma glucose (FPG) of ≥7 mmol/L)
Study: 35935634
Drug: Adequately controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequately controlled T2D (mean FPG of <7 mmol/L)
Study: 35935634
Drug: No diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No diabetes (mean FPG of ≤ 5.5 mmol/L)
Study: 35935863
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (2 g/day)
Study: 35935974
Drug: BNT162b2 Pfizer-BioNTech
Normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 Pfizer-BioNTech vaccine
Study: 35938545
Drug: Bipolar Androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar Androgen Therapy (BAT) followed by abiraterone or enzalutamide
Study: 35939367
Drug: Antiseizure medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseizure medications (ASMs)
Study: 35939367
Drug: Drug-drug interactions
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-drug interactions between ASMs
Study: 35939663
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and exercise 3 times a week for 4 weeks
Study: 35939919
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy program (MTP) applied to craniomandibular structures, four weekly sessions
Study: 35939919
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy program (MTP)
Study: 35940054
Drug: Sequential application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A)
Study: 35940054
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination of fluoropyrimidine, irinotecan, and bevacizumab (Arm B)
Study: 35940054
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment in patients older than 70 years
Study: 35940054
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment in patients with RAS mutant tumours
Study: 35940054
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment in RAS/BRAF wild-type tumours
Study: 35940055
Drug: TQ-B3139 (50-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-B3139 (50-800 mg) administered continuously in 28-day cycles, with expansion stage starting at 200 mg BID.
Study: 35940055
Drug: TQ-B3139 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-B3139 at dose level ≥200 mg BID.
Study: 35940825
Drug: Varlilumab (0.1-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varlilumab (0.1-10 mg/kg) with nivolumab (3 mg/kg) administered once every 2 weeks (Phase 1)
Study: 35940825
Drug: Varlilumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varlilumab (3 mg/kg once every 2 weeks, 3 mg/kg once every 12 weeks, and 0.3 mg/kg once every 4 weeks) with nivolumab (240 mg once every 2 weeks) (Phase 2)
Study: 35940825
Drug: Varlilumab and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varlilumab and nivolumab combination
Study: 35940836
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol (up to 20 mg) and glyceryl trinitrate (GTN) (0.8 mg and 0.4 mg)
Study: 35940836
Drug: Reduced GTN
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced GTN doses
Study: 35940836
Drug: GTN dose
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN dose reduction
Study: 35941015
Drug: Postoperative pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative pain treatment
Study: 35941028
Drug: Trastuzumab (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (loading dose 8 mg/kg, then 6 mg/kg every 3 weeks) and oral pyrotinib (400 mg per day until progression)
Study: 35941212
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose blinatumomab (maximum 112 mcg/d after initial weekly dose escalation) for 8 weeks induction and 4 weeks consolidation.
Study: 35941372
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (5.4 mg/kg bodyweight intravenously once every 3 weeks)
Study: 35941609
Drug: Formulation 3
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 3 (MMT peel powder)
Study: 35941653
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care supported by eHealth (tablet)
Study: 35941653
Drug: eHealth (tablet)
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth (tablet)
Study: 35942508
Drug: Soluble urokinase-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble urokinase-type plasminogen activator receptor (suPAR) in Stage C/D
Study: 35942675
Drug: Beta-blocker intake
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker intake
Study: 35943168
Drug: Precision cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision cancer medicine (PCM)
Study: 35943899
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin (BI) plus oral hypoglycemic drugs (OADs)
Study: 35943899
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin plus oral hypoglycemic drugs (OADs)
Study: 35944767
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) treatment
Study: 35945244
Drug: nab-paclitaxel with
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel with carboplatin followed by concomitant FHX (infusional 5-fluorouracil, hydroxyurea and twice-daily radiation therapy) plus nab-paclitaxel at a dose of 100 mg/m
Study: 35945477
Drug: Vasopressor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressor therapy (69% male vs 62% female)
Study: 35945477
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy (17% male vs 11% female)
Study: 35945477
Drug: 30-day mortality
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-day mortality after adjustment for disease severity, frailty, age and treatment limitations
Study: 35945517
Drug: PEG-rhGH 0.10-0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhGH 0.10-0.20 mg/kg/week
Study: 35945517
Drug: PEG-rhGH 0.10-0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhGH 0.10-0.14 mg/kg/week (Group A)
Study: 35945517
Drug: PEG-rhGH 0.15-0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhGH 0.15-0.20 mg/kg/week (Groups B, C, D)
Study: 35945547
Drug: E7090 (tasurgratinib),
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7090 (tasurgratinib), administered once daily as an oral single agent in 28-day cycles.
Study: 35945605
Drug: Goal-directed haemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed haemodynamic therapy (GDHT) protocol based on achieving an optimal stroke volume, systolic blood pressure > 90 mmHg, and individualized cardiac index.
Study: 35945605
Drug: Goal-directed haemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed haemodynamic therapy (GDHT) protocol
Study: 35945605
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care treatment (Control Group)
Study: 35946927
Drug: Empagliflozin/linagliptin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin/linagliptin fixed-dose combination (FDC)
Study: 35947027
Drug: Immunotherapy in
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy in the adjuvant setting
Study: 35947027
Drug: First-in-class, highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-in-class, highly selective inhibitor of KRAS G12C
Study: 35947087
Drug: Continuous Subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Subcutaneous Insulin Infusion
Study: 35947435
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo MRI angiography with contrast agent injection in the umbilical cord
Study: 35948919
Drug: Sequential epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential epirubicin and docetaxel monotherapy
Study: 35949290
Drug: GNS561 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNS561 200 mg BID
Study: 35949290
Drug: GNS561 50-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNS561 50-400 mg Q3W
Study: 35949358
Drug: Tirzepatide (GIP/GLP-1R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (GIP/GLP-1R unimolecular dual agonist)
Study: 35950205
Drug: Nilotinib 300
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 300 mg twice daily for 12 months
Study: 35950205
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg daily after switching from nilotinib
Study: 35950603
Drug: AdAPT-001 monotherapy
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdAPT-001 monotherapy
Study: 35950603
Drug: AdAPT-001 combined
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdAPT-001 combined with checkpoint inhibitor
Study: 35950621
Drug: Multikinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multikinase inhibitors
Study: 35951553
Drug: Nominal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nominal group meetings to identify treatment goals and features
Study: 35952709
Drug: Galunisertib 150
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galunisertib 150 mg twice daily for two 14-day courses before and during chemoradiotherapy.
Study: 35954555
Drug: Digital Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Care Program (DCP) consisting of exercise, education, and cognitive-behavioral therapy for 8 weeks
Study: 35957800
Drug: Antibody positive
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody positive participants
Study: 35957800
Drug: Antibody negative
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody negative participants
Study: 35957960
Drug: Vigil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigil (1 × 10e6-10e7 cells/dose intradermally, up to 12 doses) and durvalumab (1500 mg/dose intravenous infusion, up to 12 months)
Study: 35958254
Drug: Fermented oyster
Normalized name: Oyster
DrugBank: Oyster (DB10550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented oyster (FO) 1,200 mg daily for 12 weeks
Study: 35958322
Drug: Anlotinib combined
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib combined with epidermal growth factor receptor (EGFR) inhibitors in cohort A
Study: 35958322
Drug: Anlotinib combined
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib combined with EGFR inhibitors in cohort B
Study: 35958344
Drug: Concurrent platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent platinum-based chemoradiotherapy (CRT) followed by durvalumab maintenance treatment
Study: 35958398
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of aspirin (150 mg/day) in high-risk patients
Study: 35960332
Drug: Immunomodulatory five-drug
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory five-drug cocktail (IDC) + Pembrolizumab + Radiotherapy (8Gyx3)
Study: 35962368
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate orally achieving a serum level of 0.2-0.4 mmol/l between month 6 and 12
Study: 35963275
Drug: TB31F 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB31F 1 mg/kg intravenous
Study: 35963275
Drug: TB31F 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB31F 3 mg/kg intravenous
Study: 35963275
Drug: TB31F 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB31F 10 mg/kg intravenous
Study: 35963275
Drug: TB31F (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB31F (all doses)
Study: 35963480
Drug: FOLFOX-based adjuvant
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-based adjuvant chemotherapy
Study: 35964116
Drug: Usability assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usability assessment of the digital health solution
Study: 35964609
Drug: Mitapivat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitapivat (50 mg twice daily for 6 weeks, then 100 mg twice daily for 18 weeks)
Study: 35966482
Drug: Phase-oriented trauma
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase-oriented trauma treatment for 8 weeks
Study: 35967820
Drug: OEA (oleoylethanolamide)
Normalized name: Palmitoylethanolamide
DrugBank: Oleic monoethanolamide (DB16495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OEA (oleoylethanolamide) daily for 16 months
Study: 35967820
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 16 months
Study: 35968995
Drug: Early antibody-mediated
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early antibody-mediated rejection (AMR)
Study: 35968995
Drug: Late antibody-mediated
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late antibody-mediated rejection (AMR)
Study: 35969113
Drug: Low-milk dose
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-milk dose group
Study: 35969451
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment as usual + educational brochures)